Moleculin Biotech, Inc. (MBRX)
| Market Cap | 14.41M +14.4% |
| Revenue (ttm) | n/a |
| Net Income | -42.37M |
| EPS | -19.96 |
| Shares Out | 5.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 196,320 |
| Open | 2.550 |
| Previous Close | 2.500 |
| Day's Range | 2.508 - 2.770 |
| 52-Week Range | 1.790 - 24.000 |
| Beta | 1.77 |
| Analysts | Strong Buy |
| Price Target | 21.00 (+677.78%) |
| Earnings Date | May 15, 2026 |
About MBRX
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MBRX stock is "Strong Buy." The 12-month stock price target is $21.0, which is an increase of 677.78% from the latest price.
News
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
- Access the segment here
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its lead dru...
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial
Moleculin Biotech Quarterly report: Q1 2026
Moleculin Biotech has published its Q1 2026 quarterly earnings report on May 14, 2026.
Moleculin Biotech Earnings release: Q1 2026
Moleculin Biotech released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30
Moleculin Biotech (MBRX) announced it is approaching the first unblinding of data from its pivotal Phase 2B/3 “MIRACLE” trial evaluating Annamycin in combination with cytarabine for the treatment of s...
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of care First 45-subject data unblinding expected before June 30, 2026 ...
Moleculin announces publication on cardiac safety profiloe of annamycin
Moleculin Biotech (MBRX) announced the publication of an abstract at the European Hematology Association 2026 Congress highlighting the cardiac safety profile of Annamycin, the Company’s next-generati...
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction
Moleculin Biotech issued liposomal Annamycin patent in Hong Kong
Moleculin Biotech (MBRX) announced a significant advancement in its intellectual property portfolio with the issuance of a Hong Kong patent covering its proprietary method of reconstituting liposomal ...
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or th...
Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annam...
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile
Access the Moleculin CEO Corner here
Moleculin Biotech management to meet with Maxim
Meetings to be held April 8-9 hosted by Maxim.
Moleculin Biotech files to sell 6.37M shares of common stock for holders
16:02 EDT Moleculin Biotech (MBRX) files to sell 6.37M shares of common stock for holders
Moleculin Biotech Registration statement: Registration filing
Moleculin Biotech filed a registration statement on March 27, 2026, providing details about a securities offering with the SEC.
Moleculin Biotech Transcript: The 38th Annual Roth Conference
The MIRACLE phase III trial for relapsed/refractory AML is progressing rapidly, with interim unblinded data for 45 patients expected soon. Annamycin shows strong efficacy, zero cardiotoxicity, and broad organ targeting, positioning it for significant market impact and multiple upcoming milestones.
Moleculin Biotech announces enrollment milestone in MIRACLE trial
Moleculin Biotech (MBRX) announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for the treatment of adult subjec...
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 MI...
Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year
“With the MIRACLE trial rapidly progressing and the first MIRACLE interim readout now clearly within reach, we believe 2026 will be a defining year for Moleculin,” said Walter Klemp, Chairman…
Moleculin Biotech sees cash runway into 3Q26
As of December 31, 2025, the Company had cash and cash equivalents of $8.9 million and prepaid expenses and other current assets of $0.8 million. The Company also had $3.5…
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the year ended December 31, 2025 and provided a...